Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters.

Quest TL, Merrill JO, Roll J, Saxon AJ, Rosenblatt RA.

J Opioid Manag. 2012 Jan-Feb;8(1):29-38.

2.

Barriers to primary care physicians prescribing buprenorphine.

Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA.

Ann Fam Med. 2014 Mar-Apr;12(2):128-33. doi: 10.1370/afm.1595.

3.

Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Rosenblatt RA, Andrilla CH, Catlin M, Larson EH.

Ann Fam Med. 2015 Jan-Feb;13(1):23-6. doi: 10.1370/afm.1735.

4.

Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.

DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr.

Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4. Review.

5.

Steps physicians report taking to reduce diversion of buprenorphine.

Yang A, Arfken CL, Johanson CE.

Am J Addict. 2013 May-Jun;22(3):184-7. doi: 10.1111/j.1521-0391.2012.00335.x.

PMID:
23617857
6.

Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.

Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA; American Society Of Addiction Medicine.

J Addict Med. 2011 Dec;5(4):254-63. doi: 10.1097/ADM.0b013e3182312983.

PMID:
22042215
7.

Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.

Wen H, Hockenberry JM, Borders TF, Druss BG.

Med Care. 2017 Apr;55(4):336-341. doi: 10.1097/MLR.0000000000000703.

PMID:
28296674
8.

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.

Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S33-8. doi: 10.1097/QAI.0b013e3182097537.

9.

French Experience with Buprenorphine : Do Physicians Follow the Guidelines?

Guillou Landreat M, Rozaire C, Guillet JY, Victorri Vigneau C, Le Reste JY, Grall Bronnec M.

PLoS One. 2015 Oct 19;10(10):e0137708. doi: 10.1371/journal.pone.0137708. eCollection 2015.

10.

Who prescribes buprenorphine for rural patients? The impact of specialty, location and practice type in Washington State.

Kvamme E, Catlin M, Banta-Green C, Roll J, Rosenblatt R.

J Subst Abuse Treat. 2013 Mar;44(3):355-60. doi: 10.1016/j.jsat.2012.07.006. Epub 2012 Aug 30.

12.

Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S.

Ann Fam Med. 2007 Mar-Apr;5(2):146-50.

13.

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group.

N Engl J Med. 2003 Sep 4;349(10):949-58.

14.

Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.

Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, Altice FL; BHIVES Collaborative.

J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S68-75. doi: 10.1097/QAI.0b013e31820a8226.

PMID:
21317597
15.

Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

Stein BD, Pacula RL, Gordon AJ, Burns RM, Leslie DL, Sorbero MJ, Bauhoff S, Mandell TW, Dick AW.

Milbank Q. 2015 Sep;93(3):561-83. doi: 10.1111/1468-0009.12137.

16.

Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.

Mamakwa S, Kahan M, Kanate D, Kirlew M, Folk D, Cirone S, Rea S, Parsons P, Edwards C, Gordon J, Main F, Kelly L.

Can Fam Physician. 2017 Feb;63(2):137-145.

17.

Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians.

Edelman EJ, Dinh AT, Moore BA, Schottenfeld RS, Fiellin DA, Sullivan LE.

J Addict Med. 2012 Jun;6(2):159-65. doi: 10.1097/ADM.0b013e31824339fc.

18.

Preliminary survey of office-based opioid treatment practices and attitudes among psychiatrists never receiving buprenorphine training to those who received training during residency.

Suzuki J, Connery HS, Ellison TV, Renner JA.

Am J Addict. 2014 Nov-Dec;23(6):618-22. doi: 10.1111/j.1521-0391.2014.12143.x. Epub 2014 Jul 25.

19.

Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.

Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR.

Addict Behav. 2010 May;35(5):537-40. doi: 10.1016/j.addbeh.2010.01.001. Epub 2010 Jan 18.

20.

Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.

DiPaula BA, Menachery E.

J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):187-92. doi: 10.1331/JAPhA.2015.14177.

PMID:
25749264

Supplemental Content

Support Center